Systemic Delivery, Local Effects
Actym is harnessing the power of a genetically modified bacterial vehicle that can safely introduce different combinations of therapeutic payloads into the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered cancer treatment that exploits TME-specific metabolites critical for bacterial enrichment. With our approach, we aim to activate the immune response within the TME to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.
More About Our Technology